CoBrCa 2016 | Results of trial of ribociclib with everolimus and exemestane in breast cancer

Mafalda Oliveira, MD of the Vall d’Hebron University Hospital, Barcelona, Spain discusses her talk on the results of the Phase Ib trial of ribociclib (LEE011) with everolimus and exemestane in the treatment of hormone receptor-positive HER2 negative advanced breast cancer (NCT01857193) at the 2016 World Congress on Controversies in Breast Cancer (CoBrCa) in Barcelona, Spain. She explains that this trial was aimed to test whether the addition of the new drug ribociclib to exemestane and everolimus is tolerable and feasible and whether the outcomes of these patients can be improved. During her talk she gives a general overview of the dose escalation of the trial, of the most common toxicities and the response rate. She also talks about the genetic re-characterization of the tumor samples of the patients and how they are trying to find out if there are any mutations or other molecular alterations that predict response to these agents.